Belite Bio reports Phase 3 tinlarebant data at ASRS meeting

July 20, 2026 8:00 AM

Belite Bio, Inc. (NASDAQ: BLTE) reported additional secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found